(CercleFinance.com) – Inventiva announces the selection of a scientific abstract for The Liver Meeting 2022 conference, organized by the AASLD from November 4 to 8 in Washington, which assesses the correlation between the response to treatment with lanifibranor and the adiponectin level.
According to the NATIVE clinical study, treatment with lanifibranor induced a significant increase in adiponectin levels, it being noted that low adiponectin levels are associated with NASH (non-alcoholic steatohepatitis) and cardiovascular disease.
This increase is correlated with improvements in glycemic control, insulin resistance, lipid profile, liver tests and systemic inflammation, as well as fatty liver quantified by ultrasound imaging.
These data also show that lanifibranor, in addition to the beneficial effect on liver histology, improves markers of cardiometabolic health and adiponectin levels, and therefore may decrease the risk of cardiovascular disease in patients with NASH.